DAMAN enters ambitious European precision medicine healthcare project External Inbox
21 September 2022 | Wednesday | News
The SQUEEZE project planned to start early 2023 will discover new ways to maximize the impact of prescription drugs for patients suffering from the chronic autoimmune disease Rheumatoid Arthritis (RA).
Image Source : Public Domain
Digital healthcare tools and biomarkers play a key role in the project focused on overcoming real-life challenges of drug therapy by addressing behavioral and psychosocial aspects such as non-adherence, psychosocial burdens, perceptions, comorbidities, dosage of medicine etc.
Coordinated by the Medical University of Vienna, a consortium of 13 leading European organizations including university hospitals, research institutions and healthcare companies will conduct the 5-year project co-funded by Horizon Europe.
Affecting >3M patients in the EU and 17.6M worldwide, Rheumatoid Arthritis (RA) is an autoimmune chronic disease with massive impact on patients’ quality of life with significant socio-economic implications. With the SQUEEZE project new precision medicine tools will emerge:
"The SQUEEZE project is a great privilege to join – I guess it is fair to characterize the consortium as a partnership of the leading and most well-respected European stakeholders within Rheumatoid Arthritis. DAMAN’s role in the SQUEEZE project will focus on development, implementation and pilot testing of digital therapeutics based on our novelty in building next generation healthcare solutions with precision medicine. By the end of the project a digital therapeutic tool utilizing a recommendation engine for patients and healthcare professionals will be implemented," says Andreas Dam, CEO at DAMAN.
One of the world’s most renowned rheumatology scientists, Professor at the Medical University of Vienna and President-Elect of The European League Against Rheumatism (EULAR), Daniel Aletaha:
Coordinated by the Medical University of Vienna, a consortium of 13 leading European organizations including university hospitals, research institutions and healthcare companies will conduct the 5-year project co-funded by Horizon Europe.
Affecting >3M patients in the EU and 17.6M worldwide, Rheumatoid Arthritis (RA) is an autoimmune chronic disease with massive impact on patients’ quality of life with significant socio-economic implications. With the SQUEEZE project new precision medicine tools will emerge:
"The SQUEEZE project is a great privilege to join – I guess it is fair to characterize the consortium as a partnership of the leading and most well-respected European stakeholders within Rheumatoid Arthritis. DAMAN’s role in the SQUEEZE project will focus on development, implementation and pilot testing of digital therapeutics based on our novelty in building next generation healthcare solutions with precision medicine. By the end of the project a digital therapeutic tool utilizing a recommendation engine for patients and healthcare professionals will be implemented," says Andreas Dam, CEO at DAMAN.
One of the world’s most renowned rheumatology scientists, Professor at the Medical University of Vienna and President-Elect of The European League Against Rheumatism (EULAR), Daniel Aletaha:
"Over the past decades promising new treatments for Rheumatoid Arthritis have been introduced. When successful, the SQUEEZE project will enable us to match patient and medical treatment in a significantly more precise manner moving from a trial-and-error treatment regime to a brand-new and patient-focused innovative care model for Rheumatoid Arthritis. The SQUEEZE project has the potential to become a milestone for RA-patients as well as for precision medicine and precision health in general".
Most Read
- Biotech and Biopharma Industry Trends: What to Watch for in 2024
- Revolutionizing Drug Discovery: 15 AI Companies to Watch in 2024
- Pioneering Precision: Top 15 Clinical and Lab Diagnostic Companies to Watch in 2024
- 2024's Biopharma Roadmap: Top 24 Biopharma Trends to Watch in 2024
- Breakthroughs Unveiled: A Year of Groundbreaking Novel Drug Approvals in 2023
- Revolutionizing Tomorrow: Top 24 Emerging Biotech Innovations to Watch in 2024
Bio Jobs
- Leica Microsystems Announces Vacancy for Senior Imaging FPGA Testing Engineer in Singapore
- Glen Godresse Takes Helm as CEO of Menarini Asia-Pacific
- Eva van Pelt Joins Qiagen's Supervisory Board, Bringing a Wealth of Global Leadership Experience in Healthcare and Life Sciences
- Life Sciences Queensland Welcomes Dr. Kym Baker and Dr. Denise Hodge to Board Leadership
- Bayer appoints Nelson Ambrogio as new Head of Radiology Business at Pharmaceuticals Division
- Danaher Careers - Search Global Science and Technology Jobs
- Careers at MERCK Group
- Ajinomoto Bio-Pharma Services Announces Leadership Changes at US Facility
- Veranova Appoints Mike Riley as Chief Executive Officer
- Find your Job at Eppendorf
News
Editor Picks
